×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
Yahoo Finance
SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical...
4 months ago
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking...
3 weeks ago
Sagimet Biosciences stock initiated with Buy rating on denifanstat potential By Investing.com
Investing.com
On Thursday, H.C. Wainwright initiated coverage on Sagimet Biosciences Inc (NASDAQ:SGMT) with a Buy rating and set a stock price target of...
1 month ago
Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
Simply Wall Street
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
5 days ago
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Opportunity (SGMT)
Seeking Alpha
Sagimet Biosciences is a clinical-stage biopharmaceutical company researching a cure for metabolic dysfunction-related diseases by...
1 month ago
Sagimet Biosciences Names Thierry Chauche Chief Financial Officer
MarketWatch
By Colin Kellaher Sagimet Biosciences has named Thierry Chauche chief financial officer of the clinical-stage biopharmaceutical company.
1 month ago
Sagimet's shares hit new high as fatty liver disease drug shows promise in study
Reuters
Sagimet Biosciences said on Monday its experimental drug to treat a fatty liver disease significantly reduced the symptoms in a mid-stage...
4 months ago
Victory Capital Management Inc. Has $307000 Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)
Defense World
Read Victory Capital Management Inc. Has $307000 Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) at Defense World.
1 week ago
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
Yahoo Finance
SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical...
4 months ago
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
Reported positive topline data from the Phase 2b FASCINATE-2 trial; at week 52 denifanstat met both primary efficacy endpoints and...
2 months ago